Rna-based immunotherapy for glioblastoma using engineered CAR NK cells
Innovative RNA technology aims to enhance innate immunity against glioblastoma by silencing NKG2D in NK cells using siRNA, potentially transforming tumor microenvironments and improving therapeutic outcomes.
Overview
This cutting-edge research leverages RNA technology to enhance innate immune responses against glioblastoma (GBM), a highly malignant brain tumor. By silencing the NKG2D receptor in natural killer (NK) cells using small interfering RNA (siRNA), the tumor microenvironment can be reprogrammed towards a pro-inflammatory, anti-tumoral state. This approach aims to improve the interaction between NK cells and glioblastoma cells, potentially counteracting tumor growth and offering a new therapeutic avenue for GBM patients.
Technical specifications
- RNA technology: Utilizes amphiphilic dendrimers to deliver siRNA into NK cells, targeting the NKG2D receptor.
- Gene silencing: Focuses on altering NK cell activity and enhancing interactions with tumor cells, neurons, and glioma-associated macrophages (GAMs).
- In vitro and in vivo studies: Conducted using human and mouse models to validate the efficacy of silencing NKG2D in NK cells.
- Future development: Plans to engineer CAR NK cells based on insights gained from siRNA studies, aiming for an effective GBM treatment.
Technology readiness level
Currently at TRL 4, with successful laboratory validation of siRNA delivery and gene silencing in NK cells. Future stages will include further in vivo studies and the development of CAR NK cells as a novel immunotherapy for glioblastoma.
About Sapienza University of Rome
Sapienza University of Rome is a comprehensive public research university and one of Europe’s largest, with a citywide campus that integrates education, research, and clinical care. Integration with a major teaching hospital enables translational studies and large‑scale clinical collaborations. Corporate partners engage through contract research, shared facilities, training, and collaboration agreements, while proximity to ministries and national research agencies in Rome streamlines regulatory interfaces. Research is supported by competitive European Commission programs and national funding from the Italian Ministry of University and Research, with a dedicated technology transfer office managing IP, licensing, and spinout formation.
delivered to your inbox.